dc.creator | Castro Laria, Luisa | es |
dc.creator | Argüelles Arias, Federico | es |
dc.creator | García Sánchez, Valle | es |
dc.creator | Benítez, José Manuel | es |
dc.creator | Fernández Pérez, Ramón | es |
dc.creator | Trapero Fernández, Ana María | es |
dc.creator | Herrerías Gutiérrez, Juan Manuel | es |
dc.date.accessioned | 2024-05-23T15:38:07Z | |
dc.date.available | 2024-05-23T15:38:07Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Castro Laria, L., Argüelles Arias, F., García Sánchez, V., Benítez, J.M., Fernández Pérez, R., Trapero Fernández, A.M. y Herrerías Gutiérrez, J.M. (2016). Initial experience with golimumab in clinical practice for ulcerative colitis. Revista Española de Enfermedades Digestivas, 108 (3), 129-132. https://doi.org/10.17235/reed.2016.4068/2015. | |
dc.identifier.issn | 1130-0108 | es |
dc.identifier.issn | 2340-4167 | es |
dc.identifier.uri | https://hdl.handle.net/11441/158897 | |
dc.description.abstract | Background: Golimumab is a TNF-blocking agent indicated
as a second-line therapy in ulcerative colitis.
Purpose: To research the effectiveness and safety of
golimumab in patients with ulcerative colitis in clinical practice.
Methods: Retrospective study of the effectiveness and safety
of golimumab in patients with ulcerative colitis. All patients received
golimumab 200 mg subcutaneously at week 0, and golimumab
100 mg subcutaneously at week 2. After the induction treatment,
each patient received 50 mg sc. every 4 weeks in patients with body
weight less than 80 kg, and 100 mg every 4 weeks in patients with
body weight greater than or equal to 80 kg.
Results: Study of a group of 23 ulcerative colitis patients, 7 of
whom were naive to any anti-TNF therapy, and 16 patients who
had previously been treated with an anti-TNF agent other than
golimumab (non-naive patients). The average treatment time with
golimumab was 14.3 weeks. Globally, withdrawal of corticosteroids
was observed in 74% of cases. Clinical response was observed
in 85.5% of patients who had not received biological treatment
previously, and in patients who had previously received biological
treatment the response rate was 75%.
Conclusions: In this short study, golimumab seems to be an
alternative treatment in naive and non-naive anti-TNF ulcerative
colitis patients. It is also a safe therapy, given that there were no
adverse effects in the patients studied. | es |
dc.format | application/pdf | es |
dc.format.extent | 4 p. | es |
dc.language.iso | eng | es |
dc.publisher | Aran Ediciones S.A. | es |
dc.relation.ispartof | Revista Española de Enfermedades Digestivas, 108 (3), 129-132. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Golimumab | es |
dc.subject | Ulcerative colitis | es |
dc.subject | TNF-blocking agent | es |
dc.subject | Naive patient | es |
dc.subject | Non-naive patient | es |
dc.title | Initial experience with golimumab in clinical practice for ulcerative colitis | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.reed.es/ArticuloFicha.aspx?id=932&hst=0&idR=34&tp=1 | es |
dc.identifier.doi | 10.17235/reed.2016.4068/2015 | es |
dc.journaltitle | Revista Española de Enfermedades Digestivas | es |
dc.publication.volumen | 108 | es |
dc.publication.issue | 3 | es |
dc.publication.initialPage | 129 | es |
dc.publication.endPage | 132 | es |